You have 9 free searches left this month | to do more

venetoclax

Venetoclax is a drug used to treat Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, and other conditions. Venetoclax is being actively studied in 227 studies and prior, has been studied in 21.

Top SponsorsTop SitesTop Investigators
AbbVieM D Anderson Cancer CenterMatthew S. Davids, MD
M.D. Anderson Cancer CenterDana Farber Cancer InstitutePaolo Ghia
Hoffmann-La RocheMD Anderson Cancer CenterAndrew Lane
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED
N
Pharmacokinetics of Venetoclax in Patients With Acute Myeloid Leukemia
Recruiting
  • Acute Myeloid Leukemia
  • Venetoclax
  • Taipei, Taiwan
    National Taiwan University Hospital
2021-10-27
Oct 27, 2021
N
Pharmacokinetics of Venetoclax in Patients With Chronic Lymphocytic Leukemia
Recruiting
  • Chronic Lymphocytic Leukemia
  • Venetoclax
  • Taipei, Taiwan
    National Taiwan University Hospital
2021-10-27
Oct 27, 2021
D
Safe Accelerated Venetoclax Escalation in CLL
Recruiting
  • Chronic Lymphocytic Leukemia
  • Small Lymphocytic Lymphoma
  • Venetoclax
  • +2 more
  • Boston, Massachusetts
    Dana-Farber Cancer Institute
2021-09-08
Sep 8, 2021
N
A Study of Siremadlin in Combination With Venetoclax Plus Azacitidine in Adult Participants With Acute Myeloid Leukemia (AML) Who Are Ineligible for Chemotherapy.
Not yet recruiting
  • Acute Myeloid Leukemia
  • (no location specified)
2021-12-13
Dec 13, 2021
U
Cirmtuzumab Consolidation for Treatment of Patients With Detectable CLL on Venetoclax
Recruiting
  • Chronic Lymphocytic Leukemia
  • San Diego, California
    UCSD Koman Family Outpatient Pavilion
2021-11-24
Nov 24, 2021
D
Ibrutinib + Venetoclax in Untreated WM
Recruiting
  • Waldenstrom Macroglobulinemia
  • MYD88 Gene Mutation
  • Boston, Massachusetts
  • +1 more
2021-11-15
Nov 15, 2021
K
Ibrutinib and Venetoclax in Treating Patients With Chronic Lymphocytic Leukemia After Ibrutinib Resistance - 2021
Withdrawn
  • Chronic Lymphocytic Leukemia
  • Loss of Chromosome 17p
  • (no location specified)
2021-10-29
Oct 29, 2021
U
Study of Venetoclax and Azacitidine in Advanced BCR-ABL Negative Myeloproliferative Neoplasms
Not yet recruiting
  • Myeloproliferative Neoplasm
  • BCR-ABL Negative
  • Toronto, Ontario, Canada
    Princess Margaret Cancer Centre
2021-09-29
Sep 29, 2021
D
Copanlisib Plus Venetoclax in R/R DLBCL
Recruiting
  • Diffuse Large B Cell Lymphoma
  • +2 more
  • Boston, Massachusetts
    Dana-Farber Cancer Institute
2021-09-08
Sep 8, 2021
D
Venetoclax in Combination With Intensive Induction and Consolidation Chemotherapy in Treatment Naïve AML
Recruiting
  • Acute Myeloid Leukemia
  • Venetoclax
  • +2 more
  • Boston, Massachusetts
    Dana Farber Cancer Institute
2021-11-02
Nov 2, 2021
C
Venetoclax + Decitabine vs. "7+3" Induction Chemotherapy in Young AML
Recruiting
  • AML, Adult
  • Chemotherapy Effect
  • Venetoclax
  • +3 more
  • Suzhou, Jiangsu, China
    The First Affiliated Hospital of Soochow University, Jiangsu Ins
2021-12-30
Dec 30, 2021
K
Venetoclax and Obinutuzumab for Relapsed/Refractory Primary CNS Lymphoma
Suspended
  • Primary CNS Lymphoma
  • Stuttgart, Baden-Württemberg, Germany
    Klinikum Stuttgart
2021-09-15
Sep 15, 2021
H
Study of Venetoclax in Combination With Azacytidine in AML Patients Selected Using Ex Vivo Drug Sensitivity Screening
Recruiting
  • Acute Myeloid Leukemia
  • Venetoclax
  • Helsinki, Uusimaa, Finland
    HelsinkiUCH
2021-08-24
Aug 24, 2021
L
Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML)
Not yet recruiting
  • Acute Myeloid Leukemia
  • (no location specified)
2021-12-21
Dec 21, 2021
N
Early Clonal Dynamics During Venetoclax Treatment for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)
Recruiting
  • Chronic Lymphocytic Leukemia
  • Venetoclax
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
2022-01-06
Jan 6, 2022
C
Venetoclax Combined With Vyxeos (CPX-351) for Participants With Relapsed or Refractory Acute Leukemia
Suspended
  • Leukemia
  • Cincinnati, Ohio
    Cincinnati Children's Hospital Medical Center
2021-12-29
Dec 29, 2021
D
Venetoclax and Chemotherapy as Frontline Therapy in Older Patients and Patients With Relapsed/Refractory ALL
Recruiting
  • Leukemia
  • Venetoclax
  • Standard Chemotherapy
  • Boston, Massachusetts
  • +1 more
2021-08-02
Aug 2, 2021
D
Venetoclax Plus Inotuzumab for B-ALL
Recruiting
  • B-cell Acute Lymphoblastic Leukemia
  • +2 more
  • Venetoclax
  • +2 more
  • Boston, Massachusetts
  • +1 more
2021-10-19
Oct 19, 2021
A
Expanded Access to Venetoclax
Available
  • Chronic Lymphocytic Leukemia (CLL)
  • +6 more
  • Venetoclax
  • (no location specified)
2021-05-24
May 24, 2021
J
Zanubrutinib + Venetoclax in CLL/SLL
Not yet recruiting
  • Chronic Lymphocytic Leukemia (CLL)
  • Small Lymphocytic Lymphoma
  • Boston, Massachusetts
  • +2 more
2021-12-09
Dec 9, 2021
C
Venetoclax in Combination With BEAM Conditioning Regimen for ASCT in Non-Hodgkin Lymphoma
Suspended
  • Non-hodgkin Lymphoma
  • Venetoclax
  • Cleveland, Ohio
  • +1 more
2021-11-03
Nov 3, 2021
H
Venetoclax Registry
Recruiting
  • Acute Myeloid Leukemia
  • Venetoclax
  • Hannover, Niedersachsen, Germany
    Medical School Hannover
2021-02-15
Feb 15, 2021
U
Study of Enasidenib and Venetoclax in IDH2-Mutated Blood Cancers
Recruiting
  • Acute Myeloid Leukemia
  • +3 more
  • Edmonton, Alberta, Canada
  • +1 more
2021-11-29
Nov 29, 2021
O
Venetoclax and Ibrutinib in Treating in Participants With Chronic Lymphocytic Leukemia and Ibrutinib Resistance Mutations
Recruiting
  • Chronic Lymphocytic Leukemia
  • Ibrutinib Resistance
  • Columbus, Ohio
    Ohio State University Comprehensive Cancer Center
2021-10-29
Oct 29, 2021
G
Study Evaluating the Safety and Effectiveness Magrolimab Versus Placebo in Combination With Venetoclax and Azacitidine in Participants With Acute Myeloid Leukemia (AML)
Not yet recruiting
  • Acute Myeloid Leukemia
  • (no location specified)
2021-12-08
Dec 8, 2021